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Rare genetic disease in China: a call to
improve clinical services
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Patients with rare genetic diseases are becoming increas-
ingly recognised worldwide as an important public
health challenge. Despite dramatic advances in public
medicine and genomic research in China, the needs of
the rare disease patient population are far from being
met.
Lack of accurate epidemiological data in China means
that the true number of patients affected with a rare dis-
ease is unknown. 10 million is often cited, less than 1 %
of the nation’s population of 1.3 billion [1, 2]. This is
likely to be a gross underestimate. Rare diseases, most of
them being genetic in origin, are often chronic, disabling
and/or life—limiting [1]. Accepting that rare genetic dis-
ease is an enormous public health challenge is the first
step to health care and policy reform to better serve the
needs of this patient population, especially now that sci-
ence is generating results which can directly benefit this
population with enormous unmet needs. A rigorous epi-
demiological study is needed to understand the extent of
this challenge in the world’s most populous nation.
A number of important rare disease initiatives in
China have been previously reported, including the es-
tablishment of patient registries, increased funding for
translational research and advocacy for orphan drug le-
gislation [1–3]. While there is no doubt that a response
to rare disease in China needs to be multifaceted—as it
has been in Western countries—we believe that the most
important priority at present should be to systematically
improve the quality and accessibility of services for the
diagnosis of rare genetic disease.
Clinical Genetics services are offered in general hospi-
tals in China mainly through obstetrics and paediatrics
[4], but there is no minimum standard of care for the
provision of such services. The Ministry of Health does
not recognise Clinical Genetics as a medical specialty
and no formal training program exists to qualify those
obstetricians, paediatricians and laboratory personnel
who practice in this field. These physicians are under
enormous pressure to see patients quickly, with limited
time to perform the detailed clinical assessments and ex-
tensive literature searching that rare disease patients so
often require. Accessing these services is a further
challenge. With 50 % of patients in China living in
rural centres [5], distance, cost and a fragmented
province—based health system serve as barriers to
access, as services are concentrated in the most
populous cities. In non-metropolitan areas, there is
lack of awareness amongst health professionals about
the referral pathway for patients with undiagnosed
genetic conditions [6].
While next generation sequencing rapidly progresses
in China, a number of barriers limit the utilisation of
this technology for the benefit of patients with rare gen-
etic disease. Top-tier universities and tertiary hospitals
offer molecular genetic testing on a research basis but
laboratory reports are rarely issued [5]. This means that
results are seldom able to be used for management or
reproductive choices. Conversely, commercial genomics
laboratories offer next generation sequencing “diagnos-
tic” testing at a cost. While 90 % of China’s population
are covered under a universal insurance scheme, genetic
testing is excluded from coverage, so the cost is prohibi-
tive to many patients [6]. The biggest barrier is the dis-
crepancy between ability to genotype and skills to
phenotype. While it is now relatively easy to generate
vast quantities of genomic data, skills for phenotypin-
g—essential for the interpretation of genetic tests and in
predicting clinical course and mortality in rare disease
[6, 7] —are lacking.
Physicians and laboratories are challenged by the com-
plex regulatory guidelines around genetic testing. As re-
cently as February 2014, genetic testing was banned by
the Chinese FDA [8]. The wording of the ban was am-
biguous, leaving physicians and laboratories doubtful
about whether only non-invasive prenatal genomic se-
quencing or all genetic testing was covered by the ban.
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The ban has since been lifted, but physicians remain un-
easy about the legal framework around using results of
genetic testing for decision-making, particularly in the
prenatal setting. The Chinese FDA requires that every
reagent and sequencing machine in a given laboratory is
licensed for genetic testing rather than the laboratory it-
self. Many laboratories operate outside of these cumber-
some legal requirements, a factor which contributes to
the reluctance to issue diagnostic reports.
For rare disease patients unable to access a high quality
diagnostic assessment and pro-active management ser-
vices, the medical, social and economic consequences
have been well –documented [9]. Patients may receive er-
roneous diagnoses and inappropriate or inadequate man-
agement [9, 10]. Without an accurate molecular diagnosis,
genetic counselling and where appropriate, prenatal gen-
etic testing for family members at risk of recurrence can-
not be offered.
There have been dramatic improvements in health
care in China in recent decades, reflected by rapid im-
provements in life expectancy and infant mortality rates,
which are now close to those achieved in developed
countries [11, 12]. Medical care for patients with rare
genetic disease lags far behind. This public health chal-
lenge needs to be addressed by improving the level of
training in genetic disease amongst all health profes-
sionals, launching a formal professional qualification in
Clinical Genetics and establishing local and national re-
ferral centres for clinical assessment and management of
rare genetic disease. The regulations around genetic test-
ing need to be simplified and a nationally recognised
accreditation scheme for molecular genetic laborator-
ies—be they public or commercial –needs to be intro-
duced. Efforts such as establishing patient registries and
support for orphan drug legislation must continue but
their value can only be realised if rare disease patients
have access to quality diagnostic services.
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